What's Happening?
Demeetra AgBio has published a peer-reviewed study in Biotechnology Progress validating its integrated cell line development technologies for commercial bioprocessing. The study demonstrates the effectiveness of Demeetra's precision genome editing and
stable gene expression technologies in developing stable producer cell lines for biotherapeutics production. The publication provides open access to the data and methods, supporting the biomanufacturing community in advancing commercial-scale bioprocessing.
Why It's Important?
The validation of Demeetra's technologies represents a significant advancement in genome engineering and bioprocessing. By providing open access to its research, Demeetra supports innovation and collaboration within the biomanufacturing industry. This development may lead to more efficient and predictable cell line development processes, enhancing the production of biotherapeutics and potentially reducing costs and time-to-market for new treatments.
